Epstein Secrets

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

y more than $7 million in illegal kickbacks — including consulting fees, royalties and intellectual acquisition payments - for the surgeon's use of Life Spine's equipment. The suit also alleges that these agreements, spanning an estimated seven-year period, were done with the knowledge, involvement and part

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

y more than $7 million in illegal kickbacks — including consulting fees, royalties and intellectual acquisition payments - for the surgeon's use of Life Spine's equipment. The suit also alleges that these agreements, spanning an estimated seven-year period, were done with the knowledge, involvement and part

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

y more than $7 million in illegal kickbacks — including consulting fees, royalties and intellectual acquisition payments - for the surgeon's use of Life Spine's equipment. The suit also alleges that these agreements, spanning an estimated seven-year period, were done with the knowledge, involvement and part